PRECLINICAL MEDICATIONS SCREENING FOR GENETIC MODELS OF ALCOHOLISM

本合同旨在满足NIAAA神经科学和行为部临床前药物疗效测试计划的药物开发计划的当前和预期未来需求。该替代合同将继续在P大鼠和HAD 1大鼠中对参比化合物和专利化合物进行盲态试验，这些大鼠是根据酒精偏好选择性饲养的。该合同将使用具有有利于复合供应商的知识产权条件的机制。这将消除测试具有临床前和临床毒理学数据的优化化合物的主要障碍，并将激发制药行业开发高质量、可销售的酒精中毒化合物的兴趣。工作说明书的要求被认为是可分割的。

This contract is to address the present and anticipated future needs of NIAAA’s Medication Development Program of the Division of Neuroscience and Behavior’s Preclinical Medication Efficacy Testing Program. This replacement contract will continue the blind testing of reference compounds and proprietary compounds in P rats and HAD1 rats selectively bred for alcohol preference. The contract will use mechanisms having intellectual property conditions favorable to compound providers. This will eliminate a major barrier to testing optimized compounds having preclinical as well as clinical toxicology data and will stimulate interest by the pharmaceutical industry in developing high quality, marketable compounds for alcoholism. The statement of work requirements are considered to be severable.